March 28, 2021 - SCN2A Australia

Categories

Podcast

Quality of Life Measures

Measuring quality of life is important, particularly in clinical trials, to capture the broader impacts of treatment.

Sign up to the newsletter for updates.

SCN2A Asia PacificFollow

Working towards a cure for SCN2A, Raising Awareness and SCN2A Organisation for SCN2A families in Australia & across South East Asia.

Retweet on Twitter SCN2A Asia Pacific Retweeted

pedneurojournal @pedneurojournal·

6 Jan

Does genetic testing change #epilepsy treatment?

Genetic cause in 25% infant/ped onset epilepsy
- Impact treatment in 45%:
- 36% antiseizure med choice
- 7% vitamin/metabolic tx
- 3% pathway-driven off-label use med
- 10% gene-specific clinical trials
https://bit.ly/3VTqJ10

Reply on Twitter 1611392247425114112 Retweet on Twitter 161139224742511411226 Like on Twitter 161139224742511411264 Twitter 1611392247425114112

SCN2A Asia Pacific @SCN2AAustralia·

22 Dec

In 2022, SCN2A Asia Pacific has been able to increase our impact due to the support of our partners and sponsors.

We would like to thank @epilepsy_fdn for their support of our mission and for helping us with our activities in 2022. #SCN2A

Reply on Twitter 1606039569933008899 Retweet on Twitter 1606039569933008899 Like on Twitter 1606039569933008899 Twitter 1606039569933008899

SCN2A Asia Pacific @SCN2AAustralia·

22 Dec

In 2022, SCN2A Asia Pacific has been able to increase our impact due to the support of our partners and sponsors.

We would like to thank @OxPharmaGenesis for their support of our mission and for helping us with our activities in 2022. #SCN2A

Reply on Twitter 1606037590746230784 Retweet on Twitter 1606037590746230784 Like on Twitter 16060375907462307841 Twitter 1606037590746230784